| Cat. No. |
Product Name |
Information |
| PC-60492 |
CDK12 inhibitor E9 racemate
|
A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
| PC-60491 |
CDK12 inhibitor E9 R-isomer
|
A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
| PC-60480 |
Fascaplysin chloride
|
A potent CDK4/cyclin D1 with IC50 of 0.35 uM, 10-fold less potent for significantly for CDK6/cyclin D1 and does not inhibit other Cdks and tyrosine kinases. |
| PC-60479 |
CA224
|
A non-planar analogue of fascaplysin that selectively inhibits CDK4/cyclin D1 with IC50 of 5.5 uM. |
| PC-60396 |
Trilaciclib hydrochloride
|
A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
| PC-70177 |
VMY-1-103
|
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. |
| PC-70115 |
NU-6102
|
A potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively. |
| PC-60188 |
Olomoucine
|
A potent, ATP-competetive CDKs inhibitor with IC50 of 7, 7, 7, 3 uM for Cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk/p35 kinase. |
| PC-42103 |
M2I-1
|
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20. |
| PC-45599 |
NU-2058
|
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively. |
| PC-42067 |
R-547
|
A potent, selective and ATP-competitive CDK inhibitor with Ki of 1/3/1 nM for CDK1/2/4, respectively. |
| PC-45446 |
Purvalanol B
|
A potent, cell-permeable, selective inhibitor of CDK with IC50s of 6, 6, 9, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5-p35 respectively. |
